Abstract:Abstract The mammalian target of rapamycin (mTOR) is an important target for cancer chemotherapy due to the deregulation of its signaling pathway in a wide spectrum of human tumors. mTOR exists in at least two functional protein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). While rapamycin and its analogs (rapalogs) inhibit only mTORC1, ATP-competitive inhibitors of mTOR target both mTORC1 and mTORC2 and therefore have the potential for improved anticancer efficacy. We have previously reported on the pyrazolopyrimidine series of ATP-competitive mTOR inhibitors (J. Med. Chem. 2009, 52, 5013 – 5016). We now report that derivatization of the morpholine ring in these inhibitors leads to greatly enhanced mTOR selectivity versus PI3K. Selective mTOR inhibitors have the potential to achieve a higher therapeutic index in the clinic due to better tolerability. Testing these inhibitors in tumor cells and evaluating the most potent analogs in human tumor xenograft models in the nude mouse led to the identification of WYE-125132, a candidate for clinical development. WYE-125132 is also selective versus a wide range of other kinases including the closely-related PIKKs. Detailed structure activity relationships in the pyrazolopyrimidine series will be presented. In conclusion, modification of the morpholine ring of a series of pyrazolopyrimidines leads to analogs with enhanced mTOR selectivity over PI3K and potent efficacy in human tumor xenograft models in the nude mouse. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B145.

Discovery of 2-Ureidophenyltriazines Bearing Bridged Morpholines As Potent and Selective ATP-competitive Mtor Inhibitors.

Discovery of 2-Arylthieno[3,2-d]pyrimidines Containing 8-Oxa-3-azabi-cyclo[3.2.1]octane in the 4-Position As Potent Inhibitors of Mtor with Selectivity over PI3K

2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines As Highly Potent and Selective ATP Competitive Mtor Inhibitors: Optimization of Human Microsomal Stability.

Discovery of 4-Morpholino-6-aryl-1h-pyrazolo[3,4-d]pyrimidines As Highly Potent and Selective ATP-competitive Inhibitors of the Mammalian Target of Rapamycin (mtor): Optimization of the 6-Aryl Substituent.

Discovery of 3,6-Dihydro-2h-pyran As a Morpholine Replacement in 6-Aryl-1h-pyrazolo[3,4-d]pyrimidines and 2-Arylthieno[3,2-d]pyrimidines: ATP-competitive Inhibitors of the Mammalian Target of Rapamycin (Mtor)

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mtor) Inhibitors.

Triazines Incorporating (R)-3-methylmorpholine Are Potent Inhibitors of the Mammalian Target of Rapamycin (mtor) with Selectivity over Pi3k Alpha

Abstract B145: Highly Selective Pyrazolopyrimidine Mtor Inhibitors with Profound in Vivo Antitumor Activity

Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent

Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Discovery and Optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2h)-ones As Potent and Selective ATP-competitive Inhibitors of the Mammalian Target of Rapamycin (Mtor)

Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5 '-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (Pki-587), A Highly Efficacious Dual Inhibitor

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Discovery of 2-Methyl-2-(4-(2-methyl-8-(1 H -pyrrolo[2,3- b ]pyridin-6-yl)-1 H -naphtho[1,2- d ]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

ATP-competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-B]pyridazine Derivatives As Mtor Inhibitors

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.